• Novo Nordisk A/S, of Bagsvaerd, Denmark, reported data from a subgroup analysis of the A1chieve study showing that intensifying treatment with NovoMix 30 (Biphasic insulin aspart) can significantly improve blood glucose control in people with Type II diabetes who have reduced incidences of hypoglycemia.